Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMA
2023-509707-32-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Primary endpoint: Objective response rate. Planned start Feb 2024; status: authorised.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-509707-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509707-32-00.